Opdivo vs Biktarvy
Side-by-side drug price comparison from Medicare Part D data
Verdict
Biktarvy costs 76% less per claim than Opdivo ($3746.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Biktarvy at $3.8B.
| Metric | Opdivo | Biktarvy |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $15,821 | $3,746* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.1B | $3.8B |
| Total Claims | 324,000 | 1,020,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 15.8% | 12.8%* |
| Generic Available | Yes | No |
| Condition | Cancer | HIV |
| Total Beneficiaries | 66,000 | 85,000 |
Biktarvy costs 76% less per claim than Opdivo ($3746.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Biktarvy at $3.8B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.